

REMARKS

Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made." Applicant respectfully requests the entry of the above preliminary amendments.

Examiner is invited and encouraged to contact the undersigned if such contact would facilitate prosecution of this application.

No fee is believed due in connection with this Amendment, however the Commissioner is hereby authorized to charge any under-payment to Deposit Account No. 07-1392.

Respectfully submitted,

Date: 14 March 2001

Élizabeth Selby

Attorney of Record, Reg. No. 38,298

Glaxo Wellcome Inc.

Global Intellectual Property Department

Five Moore Drive, PO Box 13398

Research Triangle Park, NC 27709-3398

Telephone: 919-483-3934 Facsimile: 919-483-7988

CERTIFICATE OF EXPRESS MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner of Patents Washington, D.C. 20231 on 3//6/6/

Marilyn Eldridge



09/787323\ 532 Rec d PCT/PTO 16 MAR 200

Version with markings to show changes made

A new paragraph has been added at page 1 immediately after the title.

The abstract has been amended as follows:

The present invention provides a method for identifying a nucleic acid utilizing a run-off sequencing reaction of a relatively short portion of the nucleic acid. The method can be utilized, for example, to identify an EST from only a small portion of the EST and in an analysis of nucleotide polymorphisms. [The figure depicts an untreated and a BpmI-treated sequencing reaction.]